Memphis Pharmaceuticals & Chemical Industries (EGX:MPCI)
Egypt
· Delayed Price · Currency is EGP 170.55
-2.19 (-1.27%)
At close: Apr 28, 2026
EGX:MPCI Income Statement
Financials in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Operating Revenue | 1,675 | 1,508 | 871.91 | 663.83 | 551.26 | 518.11 | Upgrade
|
| Revenue | 1,675 | 1,508 | 871.91 | 663.83 | 551.26 | 518.11 | Upgrade
|
| Revenue Growth (YoY) | 36.21% | 72.93% | 31.34% | 20.42% | 6.40% | 6.08% | Upgrade
|
| Cost of Revenue | 990.33 | 827.82 | 571.62 | 450.88 | 401.87 | 353.14 | Upgrade
|
| Gross Profit | 685.08 | 679.98 | 300.29 | 212.95 | 149.39 | 164.98 | Upgrade
|
| Selling, General & Admin | 99.08 | 99.02 | 86.19 | 77.41 | 71.8 | 75.98 | Upgrade
|
| Other Operating Expenses | 57.94 | 58.61 | 2.69 | 39.65 | 8.55 | 54.86 | Upgrade
|
| Operating Expenses | 157.02 | 157.63 | 88.88 | 117.06 | 80.35 | 130.84 | Upgrade
|
| Operating Income | 528.06 | 522.35 | 211.41 | 95.89 | 69.04 | 34.13 | Upgrade
|
| Interest Expense | -8.16 | -13.51 | -14.26 | - | - | - | Upgrade
|
| Interest & Investment Income | 129.78 | 136.47 | 55.65 | 11.13 | 7.28 | 5.41 | Upgrade
|
| Currency Exchange Gain (Loss) | 15.72 | - | - | - | 0.67 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 4.63 | 6.56 | -23.29 | 2.96 | 1.34 | 2.11 | Upgrade
|
| EBT Excluding Unusual Items | 670.03 | 651.87 | 229.52 | 109.98 | 78.32 | 41.65 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.44 | 0.44 | - | - | - | - | Upgrade
|
| Pretax Income | 670.46 | 652.3 | 229.52 | 109.98 | 78.32 | 41.65 | Upgrade
|
| Income Tax Expense | 151.49 | 147.02 | 38.06 | 19.55 | 4.23 | -0.15 | Upgrade
|
| Net Income | 518.98 | 505.28 | 191.46 | 90.44 | 74.09 | 41.81 | Upgrade
|
| Net Income to Common | 518.98 | 505.28 | 191.46 | 90.44 | 74.09 | 41.81 | Upgrade
|
| Net Income Growth | 37.79% | 163.91% | 111.70% | 22.07% | 77.22% | 140.14% | Upgrade
|
| Shares Outstanding (Basic) | 23 | 23 | 6 | 6 | 6 | - | Upgrade
|
| Shares Outstanding (Diluted) | 23 | 23 | 6 | 6 | 6 | - | Upgrade
|
| Shares Change (YoY) | 304.44% | 304.44% | - | - | - | - | Upgrade
|
| EPS (Basic) | 22.81 | 22.21 | 34.04 | 16.08 | 13.17 | - | Upgrade
|
| EPS (Diluted) | 22.81 | 22.21 | 34.04 | 16.08 | 13.17 | - | Upgrade
|
| EPS Growth | -65.93% | -34.75% | 111.70% | 22.07% | - | - | Upgrade
|
| Free Cash Flow | -103.13 | 65.65 | 158.83 | 46.49 | 23.55 | 1.4 | Upgrade
|
| Free Cash Flow Per Share | -4.53 | 2.89 | 28.24 | 8.27 | 4.19 | - | Upgrade
|
| Dividend Per Share | 13.187 | 13.187 | 4.000 | 2.000 | - | - | Upgrade
|
| Dividend Growth | 229.67% | 229.67% | 100.00% | - | - | - | Upgrade
|
| Gross Margin | 40.89% | 45.10% | 34.44% | 32.08% | 27.10% | 31.84% | Upgrade
|
| Operating Margin | 31.52% | 34.64% | 24.25% | 14.45% | 12.52% | 6.59% | Upgrade
|
| Profit Margin | 30.98% | 33.51% | 21.96% | 13.62% | 13.44% | 8.07% | Upgrade
|
| Free Cash Flow Margin | -6.16% | 4.35% | 18.22% | 7.00% | 4.27% | 0.27% | Upgrade
|
| EBITDA | 548.96 | 542.17 | 223.59 | 103.65 | 76.68 | 43.88 | Upgrade
|
| EBITDA Margin | 32.77% | 35.96% | 25.64% | 15.61% | 13.91% | 8.47% | Upgrade
|
| D&A For EBITDA | 20.89 | 19.82 | 12.18 | 7.75 | 7.64 | 9.74 | Upgrade
|
| EBIT | 528.06 | 522.35 | 211.41 | 95.89 | 69.04 | 34.13 | Upgrade
|
| EBIT Margin | 31.52% | 34.64% | 24.25% | 14.45% | 12.52% | 6.59% | Upgrade
|
| Effective Tax Rate | 22.59% | 22.54% | 16.58% | 17.77% | 5.40% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.